论文部分内容阅读
目的比较亚胺培南 /西司他丁与头孢他啶加阿米卡星对血液系统恶性肿瘤患者并发感染的疗效。 方法治疗组 5 5例 (男 2 9例 ,女 2 6例 ;中位年龄 39岁 ) ,用亚胺培南 /西司他丁 2 g,分 1～ 2次 ,加入 5 %葡萄糖注射液5 0 0ml,静脉滴注 ;另 5 2例用头孢他啶 4g/d、阿米卡星 0 .6 g/d作对照。三组用药天数均为 7± 3d(4 ～ 10d)。 结果亚胺培南 /西司他丁和对照组的临床有效率分别为 87.3%和 71.2 % (P <0 .0 5 ) ,二组细菌转阴率分别为 71.4%和5 0 .0 % (P <0 .0 5 )。二组除少数病例出现恶心、呕吐外 ,未见严重不良反应。 结论亚胺培南 /西司他丁对血液系统恶性肿瘤并发感染疗效优于头孢他啶和阿米卡星合用。
Objective To compare the efficacy of imipenem / cilastatin with ceftazidime plus amikacin in patients with concurrent infection of hematological malignancies. Methods Fifty-five patients (29 males and 26 females; median age 39 years) were treated with imipenem / cilastatin 2 g, once or twice, and 5% glucose injection 5 0 0ml, intravenous infusion; the other 52 cases with ceftazidime 4g / d, amikacin 0 .6 g / d as a control. The days of three groups were 7 ± 3d (4 ~ 10d). Results The clinical efficacies of imipenem / cilastatin and control group were 87.3% and 71.2% (P <0.05), and the rates of bacterial negative conversion in the two groups were 71.4% and 50.0% respectively P <0. 05). In addition to a few cases of nausea and vomiting in a few cases, no serious adverse reactions. Conclusion Imipenem / cilastatin is superior to ceftazidime and amikacin in the treatment of concurrent hematological malignancies.